<DOC>
	<DOCNO>NCT00283751</DOCNO>
	<brief_summary>This trial conduct Europe United States America ( USA ) . The aim trial test Insulin Detemir add-on current Oral Antidiabetic Drug treatment least effective Insulin Glargine add-on current Oral Antidiabetic Drug treatment reduce HbA1c patient Type 2 Diabetes .</brief_summary>
	<brief_title>Comparison Insulin Detemir Insulin Glargine Add Oral Antidiabetic Drugs Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Hypoglycemic Agents</mesh_term>
	<mesh_term>Insulin Detemir</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Type 2 Diabetes 12 month , previous insulin treatment Oral Antidiabetic Drug treatment least 4 month Body Mass Index ( BMI ) less 40 kg/m2 HbA1c 7.510.0 % Current previous treatment thiazolidinediones within last 6 month Oral Antidiabetic Drug treatment combination three Oral Antidiabetic Drugs within last 6 month Proliferative retinopathy maculopathy Known hypoglycaemia unawareness</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>